EGFR and non-small cell lung carcinoma: Case studies also show that NSCLC patients with EGFR-KDD are at least partially responsive to afatinib treatment [105,110], and the third-generation TKI osimertinib has been found to be effective in patients with EGFR-KDD [111,112].